360 related articles for article (PubMed ID: 12669470)
1. Recombinant toxins for the treatment of cancer.
Kreitman RJ
Curr Opin Mol Ther; 2003 Feb; 5(1):44-51. PubMed ID: 12669470
[TBL] [Abstract][Full Text] [Related]
2. Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies.
Kreitman RJ
BioDrugs; 2009; 23(1):1-13. PubMed ID: 19344187
[TBL] [Abstract][Full Text] [Related]
3. Recombinant immunotoxins for the treatment of chemoresistant hematologic malignancies.
Kreitman RJ
Curr Pharm Des; 2009; 15(23):2652-64. PubMed ID: 19689336
[TBL] [Abstract][Full Text] [Related]
4. Immunotoxins and cytokine toxin fusion proteins.
Strom TB; Anderson PL; Rubin-Kelley VE; Williams DP; Kiyokawa T; Murphy JR
Semin Immunol; 1990 Nov; 2(6):467-79. PubMed ID: 2104283
[TBL] [Abstract][Full Text] [Related]
5. Chimeric fusion proteins--Pseudomonas exotoxin-based.
Kreitman RJ
Curr Opin Investig Drugs; 2001 Sep; 2(9):1282-93. PubMed ID: 11717817
[TBL] [Abstract][Full Text] [Related]
6. Cytotoxic activities of recombinant immunotoxins composed of Pseudomonas toxin or diphtheria toxin toward lymphocytes from patients with adult T-cell leukemia.
Kreitman RJ; Chaudhary VK; Waldmann TA; Hanchard B; Cranston B; FitzGerald DJ; Pastan I
Leukemia; 1993 Apr; 7(4):553-62. PubMed ID: 8464234
[TBL] [Abstract][Full Text] [Related]
7. Immunotoxins in cancer therapy: Review and update.
Akbari B; Farajnia S; Ahdi Khosroshahi S; Safari F; Yousefi M; Dariushnejad H; Rahbarnia L
Int Rev Immunol; 2017 Jul; 36(4):207-219. PubMed ID: 28282218
[TBL] [Abstract][Full Text] [Related]
8. Immunotoxins in the treatment of hematologic malignancies.
Kreitman RJ; Pastan I
Curr Drug Targets; 2006 Oct; 7(10):1301-11. PubMed ID: 17073592
[TBL] [Abstract][Full Text] [Related]
9. Immunotoxins for targeted cancer therapy.
Kreitman RJ
AAPS J; 2006 Aug; 8(3):E532-51. PubMed ID: 17025272
[TBL] [Abstract][Full Text] [Related]
10. Recombinant antibody fragments and immunotoxin fusions for cancer therapy.
Brinkmann U
In Vivo; 2000; 14(1):21-7. PubMed ID: 10757057
[TBL] [Abstract][Full Text] [Related]
11. Technology evaluation: BL22, NCI.
Barth S
Curr Opin Mol Ther; 2002 Feb; 4(1):72-5. PubMed ID: 11883697
[TBL] [Abstract][Full Text] [Related]
12. Toxin-labeled monoclonal antibodies.
Kreitman RJ
Curr Pharm Biotechnol; 2001 Dec; 2(4):313-25. PubMed ID: 11762413
[TBL] [Abstract][Full Text] [Related]
13. Clinical experience with denileukin diftitox (ONTAK).
Foss F
Semin Oncol; 2006 Feb; 33(1 Suppl 3):S11-6. PubMed ID: 16516670
[TBL] [Abstract][Full Text] [Related]
14. Recombinant immunotoxins for treating cancer.
FitzGerald DJ; Kreitman R; Wilson W; Squires D; Pastan I
Int J Med Microbiol; 2004 Apr; 293(7-8):577-82. PubMed ID: 15149034
[TBL] [Abstract][Full Text] [Related]
15. DAB(389)IL-2 (denileukin diftitox, ONTAK): review of clinical trials to date.
Kuzel TM
Clin Lymphoma; 2000 Nov; 1 Suppl 1():S33-6. PubMed ID: 11707861
[TBL] [Abstract][Full Text] [Related]
16. Denileukin diftitox as novel targeted therapy for lymphoid malignancies.
Wong BY; Gregory SA; Dang NH
Cancer Invest; 2007 Sep; 25(6):495-501. PubMed ID: 17882663
[TBL] [Abstract][Full Text] [Related]
17. Targeted therapy of cancer using diphtheria toxin-derived immunotoxins.
Potala S; Sahoo SK; Verma RS
Drug Discov Today; 2008 Sep; 13(17-18):807-15. PubMed ID: 18678276
[TBL] [Abstract][Full Text] [Related]
18. Recombinant immunotoxins for the treatment of haematological malignancies.
Kreitman RJ
Expert Opin Biol Ther; 2004 Jul; 4(7):1115-28. PubMed ID: 15268678
[TBL] [Abstract][Full Text] [Related]
19. Denileukin diftitox: a concise clinical review.
Eklund JW; Kuzel TM
Expert Rev Anticancer Ther; 2005 Feb; 5(1):33-8. PubMed ID: 15757436
[TBL] [Abstract][Full Text] [Related]
20. [Cancer therapy by using bispecific antibody].
Azuma A; Niitani H; Okumura K
Gan To Kagaku Ryoho; 1991 Aug; 18(10):1535-42. PubMed ID: 1872618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
